New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
05:01 EDTSODA, EXEL, CSCO, WPRT, GILD, HD, SAND, O, QCOM, GE, CELG, DVAX, BRCM, BA, CLNE, DKSJim Cramer's "Mad Money"
Jim Cramer said there are plenty of reasons to still own stocks. As many are still hopeful for a deal that can avert the fiscal cliff. So why haven't stock prices cratered in the meantime? Cramer said there are many reasons. Many investors simply aren't aware of drastic consequences if a deal is not reached, while others have their investments in IRAs and other tax-favored accounts that may not be affected by the fiscal cliff. Those investors are buyers into weakness and help provide a cushion for the markets, Cramer said. Then there are the earnings, strong earnings, from the likes of Home Depot (HD) and Dicks Sporting Goods (DKS), which prove that Americans are still spending, especially on their homes. Other big moves, including from biotechs like Celgene (CELG) and Gilead Sciences (GILD), are hard to pass up, Cramer continued. In the end, being out of the market when a deal is reached would be a huge mistake, Cramer said, as even a bad outcome is better than no outcome at all. EXECUTIVE DECISION: Cramer once again sat down with Andrew Littlefair, CEO of Clean Energy Fuels (CLNE), a stock that's been cut in half since its highs earlier this year, but also one that received a boost Tuesday on the news that the company is building two liquefied natural gas plants with General Electric (GE). Littlefair said ultimately, Clean Energy plans 10 such plants, allowing the company to provide fuel along the major interstate corridors across our country. When Westport Innovations (WPRT) introduces the next-generation natural gas engines in February, Littlefair added, that will likely be the catalyst to convince many more truckers to begin using natural gas and start saving up to $1.50 per gallon in fuel costs. Cramer said Littlefair made him feel more upbeat on the prospects for natural gas in America. OFF THE CHARTS: Cramer and colleague Bob Lang went over the chart of Boeing (BA), one that is squarely in the crosshairs of the looming fiscal cliff. With a floor at $69 a share, Lang said investors have decent downside protection at these levels. More importantly, Boeing's recent rally now puts the stock above its 10-day, 50-day and 200-day moving averages, which makes it an "up stock" in the eyes of technicians who follow it. Cramer said there's a tremendous buying cycle at hand in the aerospace world, as more and more airlines need to add more fuel efficient planes to their fleets. This cycle lasts for years, he said, which is why Boeing is one stock that can fly higher than even the fiscal cliff. NO HUDDLE OFFENSE: Cramer took a moment out to praise the management at Home Depot and Dicks Sporting Goods for their remarkable earnings.Home Depot. LIGHTNING ROUND: (Bullish) QCOM; CSCO; BRCM; O; EXEL; DVAX. (Bearish) SAND; SODA.is now set to ride the waves of a recovering housing market and the rebuilding effort after Hurricane Sandy. Cramer said Dick's 5% pop in same store sales was remarkable during a time when many are not necessarily in the market for expensive sneakers or outdoor sporting gear. Reference Link
News For HD;DKS;CELG;GILD;CLNE;GE;WPRT;BA;QCOM;CSCO;BRCM;O;EXEL;DVAX;SAND;SODA From The Last 14 Days
Check below for free stories on HD;DKS;CELG;GILD;CLNE;GE;WPRT;BA;QCOM;CSCO;BRCM;O;EXEL;DVAX;SAND;SODA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
April 3, 2014
06:28 EDTCELGAtopic dermatitis could bring upside to Regeneron, Celgene, says Citigroup
Citigroup believes Regeneron's (REGN) dupilumab and Celgene's (CELG) Otezla for atopic dermatitis are being overlooked by investors and could provide upside for both names. Citi believes both drugs have good efficacy but adds that dupilumab is more advanced. The firm has a Buy rating on both stocks.
06:23 EDTBABoeing, Airbus rivalry moves to tanker market, WSJ reports
Subscribe for More Information
06:22 EDTBABoeing to cut as man as 300 Australian contrators, WSJ reports
Boeing plans to cut as many as 300 contractors from its Boeing Aerostructures Australia facility by the end of the year, reports the Wall Street Journal. The company said, "This was always our intention when the company's aircraft programs stabilized at full production rates." Reference Link
05:59 EDTHDStocks with implied volatility movement; HD PLUG
Stocks with implied volatility movement; Home Depot (HD) 16, Plug Power (PLUG) 151 according to iVolatility.
April 2, 2014
17:41 EDTBRCMEmulex, Broadcom enter into dismissal and standstill agreement
In a regulatory filing, Emulex (ELX) announced that on March 31, Emulex and Broadcom (BRCM) entered into a dismissal and standstill agreement pursuant to which Emulex and Broadcom entered into certain understandings with respect to outstanding claims relating to and arising out of the patent infringement suit identified as Broadcom v. Emulex, Civil Action No. 8:09-cv-01058, brought by Broadcom against Emulex. Pursuant to the terms of the Dismissal Agreement: Emulex has agreed to pay Broadcom, a non-refundable, non-cancelable dismissal and standstill fee in the amount of $5M. Broadcom has agreed, for a period of one year from entering into the dismissal agreement, to provide advance notice to Emulex of future patent assertions, and to participate in good faith dispute resolution procedures; Broadcom has agreed to a one-year standstill in making any claims against Emulex, its subsidiaries or customers, or any third party suppliers of serializer/deserializer function blocks to Emulex. The standstill applies only to the extent the Broadcom claims would allege infringement of the SerDes Patents based solely on the use, manufacture, sale or import of certain Emulex products that were accused in the litigation.
16:32 EDTGILDGilead Phase 3 sofosbuvir study meets primary efficacy endpoint
Gilead Sciences announced topline results from a Phase 3 clinical trial in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin for the treatment of genotype 2 chronic hepatitis C virus infection. The study met its primary efficacy endpoint of superiority compared to a predefined historical control sustained virologic response rate. In the study, 97% of genotype 2 HCV-infected patients receiving 12 weeks of an all-oral regimen of sofosbuvir plus RBV achieved a sustained virologic response 12 weeks after completing therapy. Based on these trial results, Gilead anticipates submitting a New Drug Application for sofosbuvir to the Japanese Pharmaceutical and Medical Devices Agency by mid-2014
16:07 EDTBRCMBroadcom downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
12:33 EDTCELGOn The Fly: Midday Wrap
Subscribe for More Information
11:10 EDTBABoeing reports first order for BBJ MAX 8
Subscribe for More Information
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
09:29 EDTCELGAcceleron anemia programs get vote of confidence, says Piper Jaffray
Subscribe for More Information
09:18 EDTCELGOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTCELGCelgene to buy 1.1M shares of Acceleron Pharma for $47.15M
Subscribe for More Information
08:41 EDTCSCOPacific Crest to hold a forum
Subscribe for More Information
08:37 EDTCSCOWells Fargo to hold a summit
Subscribe for More Information
08:32 EDTGEGE gas engine technology to be used by integrated gasified biomass power plant
Subscribe for More Information
07:45 EDTGEGE Healthcare to acquire CHCA Computer Systems, terms not disclosed
Subscribe for More Information
07:23 EDTBABoeing machinists to cast ballots in rare leadership challenge, Reuters says
Boeing machinists are set to vote in a rare election for control of one of the biggest industrial unions in the U.S., a contest that could see a shift to a more militant stance if the challengers are successful, reported Reuters. Results are expected to be announced in May. Reference Link
06:21 EDTGILDGilead shares attractive at current levels, says Citigroup
Citigroup views shares of Gilead as "cheap" at current levels and keeps a Buy rating on the name with a $96 price target. Citi expects Gilead to generate $117B in free cash flow over the next 10 years and have $100B by 2023.
05:56 EDTEXELStocks with implied volatility below IV index mean; SWY EXEL
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use